MCID: CRY036
MIFTS: 38

Cryptogenic Cirrhosis

Categories: Liver diseases

Aliases & Classifications for Cryptogenic Cirrhosis

MalaCards integrated aliases for Cryptogenic Cirrhosis:

Name: Cryptogenic Cirrhosis 25
Cirrhosis, Cryptogenic 25 29 6 40 72

Classifications:



External Ids:

UMLS 72 C0267809

Summaries for Cryptogenic Cirrhosis

Genetics Home Reference : 25 Cryptogenic cirrhosis is a condition that impairs liver function. People with this condition develop irreversible liver disease caused by scarring of the liver (cirrhosis), typically in mid- to late adulthood. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. Minor damage to the liver can be repaired by the body. However, severe or long-term damage can lead to the replacement of normal liver tissue with scar tissue. In the early stages of cryptogenic cirrhosis, people often have no symptoms because the liver has enough normal tissue to function. Signs and symptoms become apparent as more of the liver is replaced by scar tissue. Affected individuals can experience fatigue, weakness, loss of appetite, weight loss, nausea, swelling (edema), enlarged blood vessels, and yellowing of the skin and whites of the eyes (jaundice). People with cryptogenic cirrhosis may develop high blood pressure in the vein that supplies blood to the liver (portal hypertension). Cryptogenic cirrhosis can lead to type 2 diabetes, although the mechanism is unclear. Some people with cryptogenic cirrhosis develop cancer of the liver (hepatocellular cancer).

MalaCards based summary : Cryptogenic Cirrhosis, also known as cirrhosis, cryptogenic, is related to liver cirrhosis and cholecystitis. An important gene associated with Cryptogenic Cirrhosis is KRT18 (Keratin 18), and among its related pathways/superpathways are Selenium Micronutrient Network and Formation of Fibrin Clot (Clotting Cascade). The drugs Zinc and Insulin Detemir have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and eye, and related phenotypes are growth/size/body region and homeostasis/metabolism

Related Diseases for Cryptogenic Cirrhosis

Diseases related to Cryptogenic Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 liver cirrhosis 32.1 KRT8 KRT18 HFE F2
2 cholecystitis 30.2 KRT18 F2
3 liver disease 30.2 KRT8 KRT18 HFE F2
4 viral hepatitis 30.1 KRT18 HFE F2
5 acute liver failure 30.1 F5 F2
6 hepatitis 30.0 KRT8 KRT18 F2
7 varicose veins 29.3 MTHFR F5 F2
8 non-alcoholic fatty liver disease 11.8
9 non-alcoholic steatohepatitis 10.6
10 fatty liver disease 10.6
11 neurenteric cyst 10.5 KRT8 KRT18
12 proliferating trichilemmal cyst 10.5 KRT8 KRT18
13 autoimmune hepatitis 10.5
14 cutaneous adenocystic carcinoma 10.5 KRT8 KRT18
15 odontoma 10.5 KRT8 KRT18
16 cervical clear cell adenocarcinoma 10.5 KRT8 KRT18
17 papillary ependymoma 10.5 KRT8 KRT18
18 mucinous tubular and spindle renal cell carcinoma 10.5 KRT8 KRT18
19 lymphoepithelioma-like carcinoma 10.5 KRT8 KRT18
20 intraneural perineurioma 10.4 KRT8 KRT18
21 nephrogenic adenofibroma 10.4 KRT8 KRT18
22 primary cutaneous amyloidosis 10.4 KRT8 KRT18
23 portal hypertension 10.3
24 primary biliary cholangitis 10.3
25 primary biliary cirrhosis 10.3
26 sweat gland cancer 10.3 KRT8 KRT18
27 hepatocellular carcinoma 10.3
28 hepatitis c 10.3
29 cholangitis 10.3
30 ameloblastoma 10.3 KRT8 KRT18
31 paracetamol poisoning 10.3 F5 F2
32 cerebral sinovenous thrombosis 10.2 F5 F2
33 chromophobe renal cell carcinoma 10.2 KRT8 KRT18
34 hemoglobin e disease 10.2 F5 F2
35 sagittal sinus thrombosis 10.2 F5 F2
36 prothrombin deficiency, congenital 10.2 F5 F2
37 blue toe syndrome 10.2 SERPINE1 F2
38 subendocardial myocardial infarction 10.2 SERPINE1 F2
39 hemochromatosis, type 1 10.2
40 hepatitis c virus 10.2
41 cholangitis, primary sclerosing 10.2
42 sclerosing cholangitis 10.2
43 oncocytoma 10.2 KRT8 KRT18
44 factor viii deficiency 10.2 F5 F2
45 peripheral vertigo 10.2 F5 F2
46 sticky platelet syndrome 10.2 SERPINE1 F5
47 hypertriglyceridemia, familial 10.2
48 dysfibrinogenemia 10.2 F5 F2
49 venous insufficiency 10.2 SERPINE1 F2
50 infective endocarditis 10.1 SERPINE1 F2

Graphical network of the top 20 diseases related to Cryptogenic Cirrhosis:



Diseases related to Cryptogenic Cirrhosis

Symptoms & Phenotypes for Cryptogenic Cirrhosis

MGI Mouse Phenotypes related to Cryptogenic Cirrhosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.92 F2 F5 HFE KRT18 KRT8 LIPA
2 homeostasis/metabolism MP:0005376 9.8 F2 F5 HFE KRT8 LIPA MTHFR
3 integument MP:0010771 9.55 F2 F5 LIPA MTHFR SERPINE1
4 liver/biliary system MP:0005370 9.5 F5 HFE KRT18 KRT8 LIPA MTHFR
5 mortality/aging MP:0010768 9.23 F2 F5 HFE KRT18 KRT8 LIPA

Drugs & Therapeutics for Cryptogenic Cirrhosis

Drugs for Cryptogenic Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
2
Insulin Detemir Approved Phase 4 169148-63-4 5311023
3
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
4
Insulin Aspart Approved Phase 4 116094-23-6 16132418
5 Insulin, Globin Zinc Phase 4
6 insulin Phase 4
7 Hypoglycemic Agents Phase 4
8 Liver Extracts Phase 4
9 Hormones Phase 4
10 Anti-Obesity Agents Phase 4
11 Incretins Phase 4
12 Hormone Antagonists Phase 4
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
14
Pentoxifylline Approved, Investigational 6493-05-6 4740
15
Metformin Approved 657-24-9 4091 14219
16
Methionine Approved, Nutraceutical 63-68-3 6137
17 Free Radical Scavengers
18 Antioxidants
19 Phosphodiesterase Inhibitors
20 Protective Agents
21 Radiation-Protective Agents
22 Platelet Aggregation Inhibitors
23 Vasodilator Agents
24 Antibodies
25 Immunoglobulins

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
2 An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Completed NCT01371825 Phase 2, Phase 3 Sebelipase alfa (SBC-102)
3 An Open Label Multicenter Extension Study to Evaluate the Long-term Efficacy and Safety of SBC-102 in Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102 Terminated NCT01473875 Phase 2, Phase 3 SBC-102
4 A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency Active, not recruiting NCT02193867 Phase 2 sebelipase alfa
5 Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome, Sepsis, Chronicle Liver Disease or After Lysis on Intensive Care Units Unknown status NCT01169168
6 Assessment of the Prevalence of Lysosomal Acid Lipase Deficiency in Patients Waiting for a Liver Transplant. Unknown status NCT02852304
7 Assessement of the Prevalence of Lysosomal Acid Lipase Deficiency in Liver Post-transplant Patients Unknown status NCT02851550
8 A Randomized Controlled Trial to Study the Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis. Unknown status NCT02231333 S-adenosylmethionine (SAMe);pentoxiphylline (PTX)
9 Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong: Natural History and Development of Liver Complications Unknown status NCT00577044
10 Prevalence and Clinical Characteristics of the Patients With Liver Cirrhosis and Different Glucose Metabolism Disorders - A Prospective Study. Unknown status NCT01396954
11 Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance: a Prospective Randomized, Open Labeled, Clinical Trial" Completed NCT02234440 Metformin;Insulin
12 The Frequency of Cholesteryl Ester Storage Disease in Children With Unexplained Transaminase Elevation and Chronic Liver Disease Completed NCT02372513
13 Undetected Bartonella Spp. Infection Puts Liver Transplant Patients at Great Risk Recruiting NCT02595710

Search NIH Clinical Center for Cryptogenic Cirrhosis

Genetic Tests for Cryptogenic Cirrhosis

Genetic tests related to Cryptogenic Cirrhosis:

# Genetic test Affiliating Genes
1 Cirrhosis, Cryptogenic 29

Anatomical Context for Cryptogenic Cirrhosis

MalaCards organs/tissues related to Cryptogenic Cirrhosis:

41
Liver, Skin, Eye, Kidney, Testes, Neutrophil, Bone

Publications for Cryptogenic Cirrhosis

Articles related to Cryptogenic Cirrhosis:

(show top 50) (show all 736)
# Title Authors PMID Year
1
Effects of Share 35 Policy on Liver Transplantation Outcomes for Patients With Nonalcoholic Steatohepatitis. 38
31146627 2019
2
Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. 38
31431413 2019
3
Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? 38
31435171 2019
4
Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. 38
31392821 2019
5
Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine. 38
31395291 2019
6
Cryptogenic liver cirrhosis and hepatitis E virus (HEV): Are they related? 38
31130469 2019
7
Position statement on the diagnosis and management of non-alcoholic fatty liver disease. 38
31219486 2019
8
Clinical course and mortality by etiology of liver cirrhosis in Sweden: a population based, long-term follow-up study of 1317 patients. 38
30957910 2019
9
Metastatic cholangiocarcinoma in a patient with undiagnosed Wilson disease. 38
31167735 2019
10
Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. 38
30676520 2019
11
NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study. 38
30861321 2019
12
Outcome of Liver Transplant Patients With Intraoperative-Detected Portal Vein Thrombosis: A Retrospective Cohort Study in Shiraz, Iran. 38
30995894 2019
13
The Frequency of Lysosomal Acid Lipase Deficiency in Children With Unexplained Liver Disease. 38
30540705 2019
14
Evaluation of Underlying Liver Disease and Its Severity in Children Referred for Liver Transplant: a Single-Center Report From Nemazee Hospital of Shiraz. 38
30836904 2019
15
Fibrinolysis Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation. 38
30548128 2019
16
Complete Heart Block due to Octreotide Infusion in Patient with Cryptogenic Cirrhosis. 38
30911266 2019
17
Senescent Hepatocytes in Decompensated Liver Show Reduced UPRMT and Its Key Player, CLPP, Attenuates Senescence In Vitro. 38
30878663 2019
18
Technical success and outcomes in pediatric patients undergoing transjugular intrahepatic portosystemic shunt placement: a 20-year experience. 38
30291382 2019
19
Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. 38
30609187 2019
20
Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis. 38
29985186 2019
21
Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis? 38
31113613 2019
22
Poor Survival After Retransplantation in NASH Cirrhosis. 38
29470354 2019
23
Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis? 38
30596627 2018
24
A decompensated cryptogenic cirrhosis? No, a late liver histiocytosis! 38
30077466 2018
25
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. 38
30144554 2018
26
Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. 38
29630771 2018
27
Significance of Occult Hepatitis C Virus Infection in Liver Transplant Patients With Cryptogenic Cirrhosis. 38
30346262 2018
28
Reply to: "NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis": Cryptogenic cirrhosis should not be equated with NASH cirrhosis based on UNOS data mining and Bayesian 'doctrine of chances'. 38
29983203 2018
29
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. 38
30227919 2018
30
A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. 38
29773419 2018
31
Clinical characteristics and outcomes of hepatocellular carcinoma: results from prospective study, from a tertiary referral center in 
Sri Lanka 38
30415518 2018
32
Pernicious anemia associated with cryptogenic cirrhosis: Two case reports and a literature review. 38
30278550 2018
33
Non-cirrhotic portal hypertension: an imaging review. 38
29564495 2018
34
Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. 38
30075518 2018
35
Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. 38
29358478 2018
36
Case report of high-dose hydroxocobalamin in the treatment of vasoplegic syndrome during liver transplantation. 38
29573551 2018
37
Role of Glutathione S Transferase M1 and T1 Gene Polymorphism in Hepatitis B Related Liver Diseases and Cryptogenic Cirrhosis. 38
29892180 2018
38
A growing hepatic mass in a cryptogenic cirrhosis patient. 38
29050462 2018
39
Raised plasma levels of H2S and nitrate predict intrapulmonary vascular dilations: A preliminary report in patients with cryptogenic cirrhosis. 38
29984390 2018
40
Prevalence of celiac disease among pediatric patients with cryptogenic cirrhosis and effect of gluten-free-diet. 38
29948993 2018
41
Telomere Length, Aggregates, and Capture in Cirrhosis. 38
29761675 2018
42
Stratifying Mortality in a Model for End-Stage Liver Disease Waiting List: A Brazilian Single-Center Study. 38
29661431 2018
43
Liver Transplantation in Cryptogenic Cirrhosis: Outcome Comparisons Between NASH, Alcoholic, and AIH Cirrhosis. 38
29215462 2018
44
Well Preserved Renal Function in Children With Untreated Chronic Liver Disease. 38
29240010 2018
45
Complete splenic embolization for the treatment of refractory ascites after liver transplantation. 38
29411988 2018
46
Follow-up Creatinine Level Is an Important Predictive Factor of In-hospital Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis. 38
29542304 2018
47
Liver Transplantation in Patients With Hepatocellular Carcinoma Outside the Milan Criteria After Downstaging: Is It Worth It? 38
29579861 2018
48
Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. 38
29359341 2018
49
Is cryptogenic cirrhosis different from NASH cirrhosis? 38
29162389 2018
50
Efficacy and Safety of Anti-TNF-α Agents in Inflammatory Bowel Disease After Liver Transplant: A Case Series. 38
29579869 2018

Variations for Cryptogenic Cirrhosis

Expression for Cryptogenic Cirrhosis

Search GEO for disease gene expression data for Cryptogenic Cirrhosis.

Pathways for Cryptogenic Cirrhosis

GO Terms for Cryptogenic Cirrhosis

Cellular components related to Cryptogenic Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.96 SERPINE1 F5
2 cell periphery GO:0071944 8.62 KRT8 KRT18

Biological processes related to Cryptogenic Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor-mediated signaling pathway GO:0033209 9.48 KRT8 KRT18
2 hemostasis GO:0007599 9.46 F5 F2
3 extrinsic apoptotic signaling pathway GO:0097191 9.43 KRT8 KRT18
4 blood circulation GO:0008015 9.4 MTHFR F5
5 acute-phase response GO:0006953 9.37 HFE F2
6 positive regulation of receptor-mediated endocytosis GO:0048260 9.32 SERPINE1 HFE
7 fibrinolysis GO:0042730 9.26 SERPINE1 F2
8 positive regulation of blood coagulation GO:0030194 9.16 SERPINE1 F2
9 hepatocyte apoptotic process GO:0097284 8.96 KRT8 KRT18
10 negative regulation of fibrinolysis GO:0051918 8.62 SERPINE1 F2

Molecular functions related to Cryptogenic Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.13 SERPINE1 HFE F2
2 scaffold protein binding GO:0097110 8.62 KRT8 KRT18

Sources for Cryptogenic Cirrhosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....